Silence Therapeutics plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company paid an executive who left, affecting shareholder value and company costs.
Companies share updated information with investors to keep them informed about progress and strategy.
Stockholder votes determine important decisions, and you own a piece of the company when you invest.
Drug trial success suggests the company's medicine works, which could increase its value and revenue.
Raising money helps fund research, but dilutes existing shareholders' ownership percentage.
Companies use sales agreements to raise cash flexibly for operations and growth when needed.
Companies raise money by selling shares, but more shares means each existing share owns less of the company.
Stocky reads Silence Therapeutics plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Silence Therapeutics plc's most recent tracked filing was a 8-K/A on 16 Jul 2026: Craig Tooman receives $1.28 million severance package.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.